Tag Archives: Seretide

Deep Breadth: GSK Doubles Down on COPD and Asthma

Will GSK be able to maintain its position in COPD and asthma, post Advair/Seretide? Despite a patent expiry in 2010, generic versions of Advair aren’t expected to appear on the market for two more years. It took FDA eight years to develop a blueprint for how generics manufacturers might establish an acceptable bioequivalence for Advair, […]
Posted in Advertising, compliance, Emerging Markets, Europe, FDA, Global, Legal, R&D, Regulatory, Sales, Strategy | Also tagged , , , , , , , | 4 Comments
  • Categories

  • Meta